Mitigation of acute lung injury by human bronchial epithelial cell-derived extracellular vesicles via ANXA1-mediated FPR signaling

Yu Fujita,Tsukasa Kadota,Reika Kaneko,Yuta Hirano,Shota Fujimoto,Naoaki Watanabe,Ryusuke Kizawa,Takashi Ohtsuka,Kazuyoshi Kuwano,Takahiro Ochiya,Jun Araya
DOI: https://doi.org/10.1038/s42003-024-06197-3
IF: 6.548
2024-05-06
Communications Biology
Abstract:Acute lung injury (ALI) is characterized by respiratory failure resulting from the disruption of the epithelial and endothelial barriers as well as immune system. In this study, we evaluated the therapeutic potential of airway epithelial cell-derived extracellular vesicles (EVs) in maintaining lung homeostasis. We isolated human bronchial epithelial cell-derived EVs (HBEC-EVs), which endogenously express various immune-related surface markers and investigated their immunomodulatory potential in ALI. In ALI cellular models, HBEC-EVs demonstrated immunosuppressive effects by reducing the secretion of proinflammatory cytokines in both THP-1 macrophages and HBECs. Mechanistically, these effects were partially ascribed to nine of the top 10 miRNAs enriched in HBEC-EVs, governing toll-like receptor-NF-κB signaling pathways. Proteomic analysis revealed the presence of proteins in HBEC-EVs involved in WNT and NF-κB signaling pathways, pivotal in inflammation regulation. ANXA1, a constituent of HBEC-EVs, interacts with formyl peptide receptor (FPR)2, eliciting anti-inflammatory responses by suppressing NF-κB signaling in inflamed epithelium, including type II alveolar epithelial cells. In a mouse model of ALI, intratracheal administration of HBEC-EVs reduced lung injury, inflammatory cell infiltration, and cytokine levels. Collectively, these findings suggest the therapeutic potential of HBEC-EVs, through their miRNAs and ANXA1 cargo, in mitigating lung injury and inflammation in ALI patients.
biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the treatment of acute lung injury (ALI). ALI is a severe lung disease, characterized by respiratory failure due to the destruction of the lung epithelial and endothelial barriers and the activation of the immune system. This disease can be caused by a variety of factors, such as bacterial or viral infections, inhalation, sepsis or trauma, etc. Although there are currently some treatment methods, such as protective ventilation, prone position and neuromuscular blockers, etc., the effects of these methods are limited. Therefore, it is crucial to develop new and effective treatment strategies to reduce lung inflammation and lung injury. In this study, the authors evaluated the therapeutic potential of extracellular vesicles (EVs) from human bronchial epithelial cells (HBECs) in maintaining lung homeostasis. Specifically, the study focused on the following aspects: 1. **Immunomodulatory effects of HBEC - EVs**: Through in vitro experiments, the immunosuppressive effects of HBEC - EVs in the LPS (lipopolysaccharide) or poly(I:C) - induced ALI cell model were studied, especially how they reduce the secretion of pro - inflammatory cytokines. 2. **miRNA and protein composition in HBEC - EVs**: Through high - throughput sequencing and proteomics analysis, the miRNAs and proteins enriched in HBEC - EVs were determined, especially those molecules related to the immune response and inflammatory pathways. 3. **Mechanism research**: The specific mechanism by which HBEC - EVs play an anti - inflammatory role by inhibiting the NF - κB signaling pathway through the interaction between ANXA1 (annexin 1) and FPR (formyl peptide receptor) 2 was explored. 4. **In vivo experimental verification**: In a mouse ALI model, the effects of HBEC - EVs on lung injury, inflammatory cell infiltration and cytokine levels were evaluated by intratracheal injection. In summary, the main objective of this paper is to explore HBEC - EVs as a new treatment method to reduce lung injury and inflammation in ALI patients through the miRNAs and proteins they carry.